Advisory Services Network buys $1,029,452 stake in Becton Dickinson and Co (BDX)

Becton Dickinson and Co (BDX) : Advisory Services Network scooped up 236 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 5,803 shares of Becton Dickinson and Co which is valued at $1,029,452.Becton Dickinson and Co makes up approximately 0.20% of Advisory Services Network’s portfolio.

Other Hedge Funds, Including , Arvest Bank Trust Division sold out all of its stake in BDX during the most recent quarter. The investment firm sold 149,006 shares of BDX which is valued $26,433,664.Mcqueen Ball Associates reduced its stake in BDX by selling 90 shares or 0.58% in the most recent quarter. The Hedge Fund company now holds 15,535 shares of BDX which is valued at $2,744,258. Becton Dickinson and Co makes up approx 1.88% of Mcqueen Ball Associates’s portfolio.First National Bank Of Mount Dora Trust Investment Services reduced its stake in BDX by selling 4 shares or 0.02% in the most recent quarter. The Hedge Fund company now holds 20,247 shares of BDX which is valued at $3,576,633. Becton Dickinson and Co makes up approx 2.00% of First National Bank Of Mount Dora Trust Investment Services’s portfolio.Chevy Chase Trust Holdings reduced its stake in BDX by selling 9,571 shares or 3.64% in the most recent quarter. The Hedge Fund company now holds 253,583 shares of BDX which is valued at $44,795,437. Becton Dickinson and Co makes up approx 0.25% of Chevy Chase Trust Holdings’s portfolio. Harbour Capital Advisors sold out all of its stake in BDX during the most recent quarter. The investment firm sold 1,475 shares of BDX which is valued $260,559.

Becton Dickinson and Co opened for trading at $177.39 and hit $177.81 on the upside on Friday, eventually ending the session at $177.4, with a gain of 0.16% or 0.29 points. The heightened volatility saw the trading volume jump to 6,17,071 shares. Company has a market cap of $37,773 M.

On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.

Many Wall Street Analysts have commented on Becton Dickinson and Co. Becton Dickinson and Co was Downgraded by Citigroup to ” Sell” on Sep 23, 2016.

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Leave a Reply

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.